ALACHUA, Fla.--(BUSINESS WIRE)--Banyan Biomarkers, Inc. announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,456,027, “Proteolytic Biomarkers for Traumatic Injury to the Nervous System”, licensed exclusively by Banyan Biomarkers from the University of Florida with the company as co-inventor. This newly issued patent describes a method of determining the presence of neural injury through the measurement of proteolytic breakdown products of microtubule-associated proteins (MAP). The company has developed Enzyme Linked Immunosorbent Assays (ELISAs) that detect MAP and is conducting a clinical study designed to evaluate MAP as an indicator of traumatic brain injury (TBI). The company’s goal is to seek FDA regulatory review for the use of MAP as an aid in the detection and monitoring of TBI.
